A study to evaluate the safety and efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in participants with chronic obstructive pulmonary disease (COPD)

Trial Identifier: 212655
Sponsor: GlaxoSmithKline
Collaborator:
NA
Start Date: June 2023
Primary Completion Date: March 2024
Study Completion Date: March 2024
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
India Ajmer, India, 305001
India Bangalore, India, 560092
India Bikaner, India, 334001
India Hyderabad, India, 500084
India Jaipur, India, 302039
India Kolkata, India, 700027
India Kolkata, India, 700014
India Kozhikode, India, 673008
India Mumbai, India, 401107
India Mysore, India, 57001
India Nagpur, India, 44009
India Nashik, India, 422007
India Pondy-Cuddalore ECR Main Road Pillaiyarkuppam Pond, India, 605402
India Pune, India, 411047